WebLUTATHERA ® (lutetium Lu 177 dotatate) is indicated for the treatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs), including foregut, midgut, and hindgut neuroendocrine tumors in adults. About GEP-NETs Frequency Classification Delay in Diagnosis Mortality Disease Progression Monitor for Progression WebAFINITOR is indicated for the treatment of adult patients with renal angiomyolipoma and tuberous sclerosis complex (TSC) not requiring immediate surgery. About Dosing & Administration Efficacy Safety Access Novartis offers a variety of patient-support opportunities—including financial assistance, counseling, a co-pay program, and more.
Launch Medical Director (Exploratory- Renal) Novartis United …
WebMay 20, 2024 · DFF332 will be tested at different doses as single agent and in combination with Everolimus (RAD001, an mTOR inhibitor), and also in combination with Spartalizumab (PDR001, an anti-PD1) plus Taminadenant (NIR178, an adenosine A2A receptor antagonist), in patients with advanced clear cell renal cell carcinoma and other malignancies with HIF … WebFeb 28, 2024 · The mystery of clinical trials. David Soergel`s career took an unusual turn when he moved from pediatric cardiology to leading drug development in the cardiovascular and renal space at Novartis. Clinical trials are at the heart of the life-changing work for patients, and Soergel believes that democratizing and demystifying them can speed up … orbwars
Novartis announces iptacopan met Phase II study primary
WebOct 26, 2024 · Basel, October 26, 2024 — Novartis today announced positive Phase II interim analysis results for iptacopan (LNP023), an investigational oral treatment for C3 glomerulopathy (C3G), presented at... WebJun 6, 2024 · Novartis products reach nearly 800 million people globally and we are finding innovative ways to expand access to our latest treatments. ... Novartis Cardio-Renal- … WebApr 14, 2024 · The Director, Launch Medical will act as a subject matter expert in the development of the overarching strategies, providing inputs during design and along the end-to-end execution of programs. The Medical Director, Launch Medical will provide leadership and deep medical expertise across TAs, pivoting support based on business priorities. ippon teddy riner